This article contains links to products or services from one or more of our advertisers or partners. We may receive a commission when you click or make a purchase using our site. Learn more about how we make money.

How to buy Odonate Therapeutics stock | $16.31

Own Odonate Therapeutics stock in just a few minutes.

Posted

Fact checked

Odonate Therapeutics, Inc is a biotechnology business based in the US. Odonate Therapeutics shares (ODT) are listed on the NASDAQ and all prices are listed in US Dollars. Odonate Therapeutics employs 134 staff and has a market cap (total outstanding shares value) of USD$572.1 million.

How to buy shares in Odonate Therapeutics

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Odonate Therapeutics. Find the stock by name or ticker symbol: ODT. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Odonate Therapeutics reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$16.31, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Odonate Therapeutics, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Odonate Therapeutics. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Odonate Therapeutics share price

Use our graph to track the performance of ODT stocks over time.

Odonate Therapeutics shares at a glance

Information last updated 2020-11-27.
Latest market close USD$16.31
52-week range USD$12.56 - USD$46.5
50-day moving average USD$15.0329
200-day moving average USD$26.5375
Wall St. target price USD$35
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-4.461

Buy Odonate Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Vanguard
$0
Stocks, Mutual funds, ETFs, Forex
$1
$20 per year
Get a personal advisor when you open an account with at least $50,000.
Robinhood
$0
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, Index funds, ETFs, Futures, Cash
$0 + $0.65/contract, $1 minimum
0%
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
TD Ameritrade
$0
or $25 broker-assisted
Stocks
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.
Moomoo
$0 for US stocks
Stocks, Options, ETFs
$0
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
loading

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Odonate Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Odonate Therapeutics price performance over time

Historical closes compared with the close of $16.31 from 2020-12-04

1 week (2020-11-25) N/A
1 month (2020-11-02) N/A
3 months (2020-09-02) N/A
6 months (2020-06-02) N/A
1 year (2019-12-02) N/A
2 years (2018-12-02) N/A
3 years (2017-12-02) N/A
5 years (2015-12-02) N/A

Odonate Therapeutics financials

Gross profit TTM USD$0
Return on assets TTM -37.55%
Return on equity TTM -69.31%
Profit margin 0%
Book value $4.298
Market capitalisation USD$572.1 million

TTM: trailing 12 months

Shorting Odonate Therapeutics shares

There are currently 2.5 million Odonate Therapeutics shares held short by investors – that's known as Odonate Therapeutics's "short interest". This figure is 19.2% up from 2.1 million last month.

There are a few different ways that this level of interest in shorting Odonate Therapeutics shares can be evaluated.

Odonate Therapeutics's "short interest ratio" (SIR)

Odonate Therapeutics's "short interest ratio" (SIR) is the quantity of Odonate Therapeutics shares currently shorted divided by the average quantity of Odonate Therapeutics shares traded daily (recently around 244992.52427184). Odonate Therapeutics's SIR currently stands at 10.3. In other words for every 100,000 Odonate Therapeutics shares traded daily on the market, roughly 10300 shares are currently held short.

However Odonate Therapeutics's short interest can also be evaluated against the total number of Odonate Therapeutics shares, or, against the total number of tradable Odonate Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Odonate Therapeutics's short interest could be expressed as 0.08% of the outstanding shares (for every 100,000 Odonate Therapeutics shares in existence, roughly 80 shares are currently held short) or 0.1559% of the tradable shares (for every 100,000 tradable Odonate Therapeutics shares, roughly 156 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Odonate Therapeutics.

Find out more about how you can short Odonate Therapeutics stock.

Odonate Therapeutics share dividends

We're not expecting Odonate Therapeutics to pay a dividend over the next 12 months.

Odonate Therapeutics share price volatility

Over the last 12 months, Odonate Therapeutics's shares have ranged in value from as little as $12.56 up to $46.5. A popular way to gauge a stock's volatility is its "beta".

ODT.US volatility(beta: 0.62)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Odonate Therapeutics's is 0.6174. This would suggest that Odonate Therapeutics's shares are less volatile than average (for this exchange).

Odonate Therapeutics overview

Odonate Therapeutics, Inc., a pharmaceutical company, develops therapeutics for the treatment of cancer. It is developing tesetaxel, an orally administered chemotherapy agent, which is in Phase III clinical study for patients with locally advanced or metastatic breast cancer; and CONTESSA 2 and CONTESSA TRIO, which is in Phase II clinical study for central nervous system metastases and various cancer treatments. The company was founded in 2013 and is based in San Diego, California.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site